Enanta Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US29251M1062

SecurityENTA / Enanta Pharmaceuticals, Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership240,968 shares
Latest Disclosed Value $ 3,043,426
Northern Trust Corp reports 4.82% increase in ownership of ENTA / Enanta Pharmaceuticals, Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 240,968 shares of Enanta Pharmaceuticals, Inc. (US:ENTA) valued at $3,043,426 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 229,889 shares of Enanta Pharmaceuticals, Inc.. This represents a change in shares of 4.82% during the quarter. The current value of the position is $2,826,555 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 240,968 11,079 4.82 3,043 -16.06 0.0001
2026-02-17 2025-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 229,889 33,993 17.35 3,625 54.65 0.0001
2025-11-14 2025-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 195,896 -55,318 -22.02 2,345 23.43 0.0001
2025-08-13 2025-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 251,214 -69,298 -21.62 1,899 7.35 0.0003
2025-05-13 2025-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 320,512 -66,864 -17.26 1,769 -20.57 0.0003
2025-02-14 2024-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 387,376 -149,329 -27.82 2,227 -59.95 0.0003
2024-11-13 2024-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 536,705 -308,411 -36.49 5,560 -49.27 0.0009
2024-08-14 2024-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 845,116 -88,240 -9.45 10,961 -32.74 0.0018
2024-05-14 2024-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 933,356 -2,137 -0.23 16,296 85.14 0.0028
2024-02-13 2023-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 935,493 -24,413 -2.54 8,803 -17.91 0.0016
2023-11-13 2023-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 959,906 -14,871 -1.53 10,722 -48.60 0.0021
2023-08-11 2023-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 974,777 111,461 12.91 20,860 -40.25 0.0040
2023-05-15 2023-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 863,316 -19,814 -2.24 34,912 -15.02 0.0069
2023-02-13 2022-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 883,130 -81,277 -8.43 41,083 -17.87 0.0086
2022-11-14 2022-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 964,407 33,116 3.56 50,023 13.63 0.0114
2022-08-12 2022-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 931,291 3,198 0.34 44,022 -33.36 0.0094
2022-05-13 2022-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 928,093 -84,071 -8.31 66,061 -12.72 0.0116
2022-02-08 2021-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 1,012,164 53,116 5.54 75,689 38.92 0.0124
2021-11-15 2021-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 959,048 310,246 47.82 54,483 90.81 0.0096
2021-08-13 2021-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 648,802 3,888 0.60 28,554 -10.23 0.0050
2021-05-12 2021-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 644,914 407,185 171.28 31,807 217.78 0.0059
2021-02-11 2020-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 237,729 -10,312 -4.16 10,009 -11.85 0.0019
2020-11-16 2020-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 248,041 -6,619 -2.60 11,355 -11.20 0.0025
2020-08-14 2020-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 254,660 -3,906 -1.51 12,787 -3.84 0.0030
2020-05-14 2020-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 258,566 24,268 10.36 13,298 -8.14 0.0038
2020-02-14 2019-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 234,298 -7,349 -3.04 14,476 -0.29 0.0032
2019-11-13 2019-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 241,647 7,610 3.25 14,518 -26.49 0.0035
2019-08-13 2019-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 234,037 2,657 1.15 19,749 -10.64 0.0047
2019-05-13 2019-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 231,380 -9,423 -3.91 22,101 29.59 0.0055
2019-02-12 2018-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 240,803 9,207 3.98 17,055 -13.83 0.0048
2018-11-14 2018-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 231,596 7,653 3.42 19,792 -23.74 0.0048
2018-09-18 2018-06-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 223,943 32,113 16.74 25,955 67.23 0.0066
2018-08-14 2018-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 225,155 33,325 26,096
2018-05-09 2018-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 191,830 -8,527 -4.26 15,521 32.01 0.0040
2018-02-14 2017-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 200,357 4,834 2.47 11,757 28.48 0.0030
2017-11-13 2017-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 195,523 -189 -0.10 9,151 29.97 0.0024
2017-08-11 2017-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 195,712 7,772 4.14 7,041 21.63 0.0020
2017-05-12 2017-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 187,940 -2,371 -1.25 5,789 -9.19 0.0017
2017-02-13 2016-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 190,311 7,494 4.10 6,375 31.06 0.0020
2016-11-09 2016-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 182,817 5,770 3.26 4,864 24.59 0.0015
2016-08-12 2016-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 177,047 -9,326 -5.00 3,904 -28.69 0.0013
2016-08-19 2016-03-31 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 186,373 5,104 2.82 5,475 -8.52 0.0018
2016-05-13 2016-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 186,373 5,475
2016-02-12 2015-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 181,269 4,110 2.32 5,985 -6.51 0.0020
2015-11-12 2015-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 177,159 47,120 36.24 6,402 9.44 0.0021
2015-08-13 2015-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 130,039 9,363 7.76 5,850 58.28 0.0040
2015-05-14 2015-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 120,676 143 0.12 3,696 -39.70 0.0011
2015-02-12 2014-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 120,533 -789 -0.65 6,129 27.69 0.0019
2014-11-13 2014-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 121,322 64,879 114.95 4,800 97.45 0.0015
2014-08-14 2014-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 56,443 5,204 10.16 2,431 18.64 0.0008
2014-05-14 2014-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 51,239 -2,274 -4.25 2,049 40.34 0.0006
2014-02-21 2013-12-31 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 53,513 3,977 8.03 1,460 28.63 0.0005
2014-02-12 2013-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 53,513 1,460
2013-11-13 2013-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 49,536 36,138 269.73 1,135 378.90 0.0004
2013-08-09 2013-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 13,398 13,398 237 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.